M1 Kliniken AG

  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 07.05.2018 | 13:00

M1 Kliniken AG confirms preliminary figures for 2017 and will continue on its profitable growth path

DGAP-News: M1 Kliniken AG / Key word(s): Final Results/Dividend

07.05.2018 / 13:00
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG confirms preliminary figures for 2017 and will continue on its profitable growth path

- Sales EUR 47.2 million (+31.3%), EBT EUR 7.4 million (+34.2%)

- Dividend of EUR 0.30 per share planned

- Equity ratio of 93%: strong foundation for growth

- Outlook positive: Sales and earnings to be further increased

Berlin, 07.05.2018 - M1 Kliniken AG (ISIN: DE000A0STSQ8), the leading private provider of health services in the field of beauty medicine in Germany, today published its 2017 consolidated financial statements and confirmed its preliminary figures. The group benefits from the increasing demand for plastic and aesthetic beauty treatments in Germany. The profitable growth course is to be continued in the current year and the international expansion is to begin.

In 2017, the Group again significantly increased its sales and profits. Revenues increased by 31.3% from EUR 36.0 million in 2016 to EUR 47.2 million. The result from ordinary activities (EBT) rose by 34.2% from Euro 5.5 million in 2016 to Euro 7.4 million. Undiluted earnings per share were EUR 0.38 (previous year: EUR 0.30). A dividend of EUR 0.30 per share will be proposed at the Annual General Meeting.

"Our specialization in selected treatments within the field of beauty medicine enables us to offer top-class medicine at an attractive price. On the basis of this strategy, we see considerable growth potential in Germany and beyond in the coming years," says Patrick Brenske, member of the Management Board of M1 Kliniken AG. "With an equity ratio of over 93%, we have a strong financial foundation to consistently exploit this potential."

The M1 Group is optimistic about the future: The growth driver is "M1 Med Beauty", the leading brand for aesthetic and plastic treatments in Germany. M1 now operates a Germany-wide network of 19 ambulatory specialist centres for beauty treatments after opening two further locations in the first quarter of 2018. The expansion of the network will continue in 2018.

This also applies to the surgical field: M1 operates the Schlossklinik in Berlin, one of the largest and most modern specialist clinics for plastic and aesthetic medicine in Europe. The available operating theatre capacities are to be strengthened in the current year through the development of a second clinic location in Essen and the acquisition of occupancy capacities in other cities. This makes it possible to offer patients surgical services in the vicinity of their place of residence throughout Germany. In addition, the start of the international expansion is planned for the current year.

The Annual Report 2017 of M1 Kliniken AG is available for download at www.m1-kliniken.de

About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of health care services in the field of beauty medicine in Germany. In the aesthetic and surgical field, the Group offers products and services of the highest quality standard. Under the brand name "M1 Med Beauty", a network of currently 19 ambulatory specialist centres for beauty treatments and a surgical clinic is operated. With six operating theatres and 35 beds, the M1 Schlossklinik Berlin is one of the largest and most modern facilities of its kind in Europe. The Group also markets high-quality products to doctors, pharmacies and wholesalers. www.m1-kliniken.de/en

Details of the M1 Kliniken AG share
Subscribed capital: EUR 16,500,000
Class of shares: Bearer shares
ISIN: DE000A0STSQ8 * WKN: A0STSQ * Stock exchange symbol: M12

M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de

07.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

Über 50% Kurschance bei Homes & Holiday AG, Börsengang läuft!

Der Ferienimmobilienspezialist geht zur Wachstumsbeschleunigung an die Börse. Die Zeichnungsfrist für die Homes & Holiday-Aktie (DE000A2GS5M9) läuft noch bis zum 21. Juni, Zeichnungen sind möglich per Kauforder am Börsenplatz München zu einem Preis von 2,50 €. Die Positionierung in Europas attraktivsten Ferienimmobilienregionen ist hervorragend. In Mallorca ist die Tochtergesellschaft Porta Mallorquina unter den TOP-3-Maklerhäusern, der Fokus des weiteren Wachstum liegt auf Standorten in Spanien und Deutschland. Dort befinden sich die Preise im starken Aufwärtstrend. Unser Research sieht den fairen Wert nach IPO bei 4,83 € je Aktie und damit eine hohe Kurschance.

News im Fokus

Daimler AG: Daimler passt Ergebnis-Erwartungen an

20. Juni 2018, 22:05

Aktuelle Research-Studie

artec technologies AG

Original-Research: artec technologies AG (von GBC AG): Kaufen

20. Juni 2018